Venkat Shankar1, Anwarul Haque2, Kevin B Churchwell2, William Russell3. 1. Division of Pediatric Critical Care Medicine, Suite 5121 Doctors Office Tower, 2200 Children's Way, 37232-9075, Nashville, TN, USA. vshankarmd@mac.com. 2. Division of Pediatric Critical Care Medicine, Suite 5121 Doctors Office Tower, 2200 Children's Way, 37232-9075, Nashville, TN, USA. 3. Division of Pediatric Endocrinology, Monroe Carrell Jr. Children's Hospital at Vanderbilt, 37232, Nashville, TN, USA.
Abstract
OBJECTIVE: To study the effect of subcutaneous administration of insulin glargine on the rate of resolution of acidosis and intravenous insulin infusion requirement in children with moderate and severe diabetic ketoacidosis (DKA). STUDY DESIGN: Retrospective cohort study. SETTING: Pediatric intensive care unit of a university-based children's hospital. PATIENTS: Children with moderate to severe DKA admitted between March 2001 and February 2003. RESULTS: The outcomes of children who received 0.3 units/kg of subcutaneous insulin glargine in the first 6 h of management in addition to the standard treatment (n=12) were compared with those of children who received standard treatment alone (n=59). Measured outcomes included dose of intravenous insulin required, duration of insulin infusion and acidosis correction time. The two groups were similar in demographics and severity of illness. The mean time for acidosis correction (venous pH>or=7.3) in the insulin glargine group was shorter than the standard therapy group (12.4+/-2.9 h and 17.1+/-6.2 h respectively, p<0.001). The insulin infusion time was shorter in the insulin glargine group (14.8+/-6.0 h vs 24.4+/-9.0 h, p<0.001). There was a trend towards shorter total hospital stay in the glargine group (3.2+/-1.0 days vs 3.72+/-1.06 days). CONCLUSIONS: In our small series of children with moderate and severe DKA, supplementing with subcutaneous insulin glargine led to a faster resolution of acidosis without any adverse effects. This could potentially lead to a shorter need for insulin infusion and a shorter ICU length of stay.
OBJECTIVE: To study the effect of subcutaneous administration of insulinglargine on the rate of resolution of acidosis and intravenous insulin infusion requirement in children with moderate and severe diabetic ketoacidosis (DKA). STUDY DESIGN: Retrospective cohort study. SETTING: Pediatric intensive care unit of a university-based children's hospital. PATIENTS: Children with moderate to severe DKA admitted between March 2001 and February 2003. RESULTS: The outcomes of children who received 0.3 units/kg of subcutaneous insulinglargine in the first 6 h of management in addition to the standard treatment (n=12) were compared with those of children who received standard treatment alone (n=59). Measured outcomes included dose of intravenous insulin required, duration of insulin infusion and acidosis correction time. The two groups were similar in demographics and severity of illness. The mean time for acidosis correction (venous pH>or=7.3) in the insulinglargine group was shorter than the standard therapy group (12.4+/-2.9 h and 17.1+/-6.2 h respectively, p<0.001). The insulin infusion time was shorter in the insulinglargine group (14.8+/-6.0 h vs 24.4+/-9.0 h, p<0.001). There was a trend towards shorter total hospital stay in the glargine group (3.2+/-1.0 days vs 3.72+/-1.06 days). CONCLUSIONS: In our small series of children with moderate and severe DKA, supplementing with subcutaneous insulinglargine led to a faster resolution of acidosis without any adverse effects. This could potentially lead to a shorter need for insulin infusion and a shorter ICU length of stay.
Authors: A Wagner; A Risse; H L Brill; V Wienhausen-Wilke; M Rottmann; K Sondern; B Angelkort Journal: Diabetes Care Date: 1999-05 Impact factor: 19.112
Authors: Abbas E Kitabchi; Guillermo E Umpierrez; Mary Beth Murphy; Eugene J Barrett; Robert A Kreisberg; John I Malone; Barry M Wall Journal: Diabetes Care Date: 2003-01 Impact factor: 19.112
Authors: Arleta Rewers; H Peter Chase; Todd Mackenzie; Philip Walravens; Mark Roback; Marian Rewers; Richard F Hamman; Georgeanna Klingensmith Journal: JAMA Date: 2002-05-15 Impact factor: 56.272
Authors: N Glaser; P Barnett; I McCaslin; D Nelson; J Trainor; J Louie; F Kaufman; K Quayle; M Roback; R Malley; N Kuppermann Journal: N Engl J Med Date: 2001-01-25 Impact factor: 91.245
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-02-29 Impact factor: 17.440
Authors: V Sanoe Harrison; Stacy Rustico; Andrew A Palladino; Christine Ferrara; Colin Patrick Hawkes Journal: Pediatr Diabetes Date: 2016-11-03 Impact factor: 4.866
Authors: Tara T T Tran; Anthony Pease; Anna J Wood; Jeffrey D Zajac; Johan Mårtensson; Rinaldo Bellomo; Elif I I Ekinci Journal: Front Endocrinol (Lausanne) Date: 2017-06-13 Impact factor: 5.555
Authors: Stephen H Rappaport; Jeffrey A Endicott; Matthew P Gilbert; Joshua D Farkas; Ryan D Clouser; Wesley D McMillian Journal: J Endocr Soc Date: 2019-04-11